

## COMPANY OVERVIEW

BioCorRx® is a leading-edge healthcare solutions company focused on improving the lives of those struggling with alcohol, opioid, and other addictive disorders. Designed to address alcoholism and certain opioid addictions, the BioCorRx® Recovery Program is used by independent treatment centers or physicians in the United States. The program consists of BioCorRx's proprietary cognitive behavioral therapy (CBT) program and peer recovery support mobile application and may include the use of certain medications typically used for the treatment of substance use disorder (SUD). Which medication used, if any, is at the sole discretion of the treating physician in consultation with their patient. The most common medication used in the program is naltrexone in various forms (oral, injectable, implantable pellet). The company does not sell, manufacture, or compound any drugs or pharmaceuticals. The company also has a pharmaceutical subsidiary, BioCorRx Pharmaceuticals, which is developing medications for future regulatory approval. Its lead candidate is BICX102, a biodegradable implantable naltrexone pellet for alcohol and opioid use disorders.

## RECENT NEWS

### [BioCorRx Announces Update on NIDA Grant and Development of Naltrexone Implant for the Treatment of Opioid and Alcohol Use Disorders](#)

Jan 15 2021, 8:30 AM EST

### [BioCorRx Provides Business Update for the Third Quarter of 2020; BioCorRx Subsidiary, BioCorRx Pharmaceuticals Inc. Progressing with Pivotal Nonclinical BICX102 Study](#)

Nov 16 2020, 8:30 AM EST

### [BioCorRx Partners with Truusight Health to Integrate Recovery Program Into Self-Funded Health Plans](#)

Oct 13 2020, 8:30 AM EDT

## STOCK OVERVIEW

Symbol	BICX
Exchange	OTCQB
Market Cap	7.81m
Last Price	\$1.45
52-Week Range	\$0.16 - \$3.50

01/19/2021 03:41 PM EST

## INVESTOR RELATIONS

Crescendo Communications, LLC  
T: 212-671-1020 x304  
[bicx@crescendo-ir.com](mailto:bicx@crescendo-ir.com)  
[investors@biocorr.com](mailto:investors@biocorr.com)

## MANAGEMENT TEAM

### **Lourdes Felix**

CEO, CFO and Director

### **Brady Granier**

President and Director

### **Dr. Balbir S. Brar**

Senior VP of Drug Development

### **Tom Welch**

VP of Operations

### **Dr. George Fallieras**

Medical Consultant

## BIOCORRX, INC.

2390 E. Orangewood Ave.  
Suite 500  
Anaheim, CA 92806

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.

